Who Paid My Doc
Vasileios Assikis
Hematology & Oncology Newnan, GA Medical Doctor
NPI 1730147596 CMS profile 78781
775 Poplar Rd Ste 310, Newnan, GA 30265
General payments
$61,701
Research payments
$1,270
Ownership & investment interest
$0
Research they led as principal investigator
$3,088,223
Through program year 2025, Vasileios Assikis of Newnan, GA is reported in the CMS Open Payments database as having received $61,701 across 346 general payments and $1,270 in research payments paid to them. Separately, studies naming them as principal investigator received $3,088,223 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,959 | 41 | |
| 2025 | Research | $1,270 | 2 | |
| 2024 | General | $11,028 | 53 | |
| 2023 | General | $7,973 | 30 | |
| 2022 | General | $8,501 | 26 | |
| 2021 | General | $16,399 | 41 | |
| 2020 | General | $9,012 | 57 | |
| 2019 | General | $6,830 | 98 |
Beside peers
- Vasileios Assikis
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Vasileios Assikis were reported at $1,959. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Vasileios Assikis | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $6,830 | $529 | $121–$2,516 | $163 |
| 2020 | $9,012 | $339 | $82–$2,213 | $114 |
| 2021 | $16,399 | $263 | $49–$1,965 | $132 |
| 2022 | $8,501 | $416 | $103–$2,395 | $149 |
| 2023 | $7,973 | $542 | $125–$2,646 | $160 |
| 2024 | $11,028 | $692 | $141–$3,008 | $164 |
| 2025 | $1,959 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 65 drugsPart D claims
3,225
Drug cost
$10,689,135
Branded share of claims
41.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | Brand | 144 | $1,619,713 | |
| Erleada Apalutamide | Brand | 119 | $1,594,515 | |
| Revlimid Lenalidomide | Brand | 85 | $1,385,176 | |
| Nubeqa Darolutamide | Brand | 82 | $987,883 | |
| Lupron Depot Leuprolide Acetate | Brand | 134 | $807,814 | |
| Cabometyx Cabozantinib S-Malate | Brand | 25 | $731,351 | |
| Brukinsa Zanubrutinib | Brand | 46 | $607,693 | |
| Abiraterone Acetate | Generic | 284 | $570,254 | |
| Verzenio Abemaciclib | Brand | 33 | $376,172 | |
| Ibrance Palbociclib | Brand | 26 | $352,924 |
The 10 drugs with the highest cost, of 65 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 143 billing codesPaid by Medicare
$5,706,432
Medicare patients
830
Services billed
243,465
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 62% | |
| Arthritis | 40% | |
| Ischemic heart disease | 36% | |
| Chronic kidney disease | 33% | |
| Diabetes | 28% | |
| Heart failure | 21% | |
| Atrial fibrillation | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 27 | 28,600 | $1,204,335 |
| Injection, nivolumab, 1 mg J9299 | Office | 15 | 33,400 | $735,067 |
| Injection, denosumab, 1 mg J0897 | Office | 56 | 14,640 | $284,694 |
| Injection, triptorelin pamoate, 3.75 mg J3315 | Office | 39 | 366 | $114,069 |
| Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg Q5112 | Office | 11 | 2,244 | $59,586 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg Q5123 | Office | 11 | 2,039 | $58,879 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | Office | 29 | 99 | $50,136 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 30 | 3,100 | $46,200 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 13 | 16,800 | $36,770 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 44 | 278 | $34,604 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 29 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Trodelvy |
|
$7,129 | — | — |
| Lenvima |
|
$3,000 | 11 | — |
| TUKYSA |
|
$104 | — | — |
| VENCLEXTA |
|
$92 | — | — |
| BRUKINSA |
|
$77 | 46 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 29 with PatronRecords
348 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Georgia
Priya Rudolph
Hematology & Oncology · Athens, GA
Aron Kefela
Hematology & Oncology · Hiram, GA
Chandar Bhimani
Hematology & Oncology · Conyers, GA
Ticiana Leal
Hematology & Oncology · Atlanta, GA
Steven McCune
Hematology & Oncology · Marietta, GA
Jorge Leguizamo
Hematology & Oncology · Lawrenceville, GA
Related records
Hematology & Oncology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.